Submitted on January 10, 2002
From the Center for Molecular Imaging Research (C.-H.T., U.M., V.N., R.W.) and the Cardiovascular Research Center and Cardiology Division (J.C., R.G., M.C.F., P.L.H.), Massachusetts General Hospital, Harvard Medical School, Boston. * To whom correspondence should be addressed. E-mail: weissleder{at}helix.mgh.harvard.edu.
BackgroundAtherosclerotic plaque rupture, the most important cause of acute cardiovascular incidents, has been strongly associated with vascular inflammation. On the basis of the hypothesis that the inflammatory response and proteolysis lead to plaque rupture, we have examined the role of cathepsin B as a model proteolytic enzyme. Methods and ResultsUsing western-type diet--fed apoE and apoE/endothelial NO synthase double knockout mice as models of atherosclerosis, we show (1) that cathepsin B is upregulated in atherosclerotic lesions characterized by high degrees of inflammation compared with normal aorta or silent lesions, (2) that intravenously injectable novel cathepsin B imaging beacons are highly activated within active atherosclerotic lesions and colocalize with cathepsin B immunoreactivity, and (3) that cathepsin B activity in atherosclerotic lesions can be imaged in whole animals by using a novel near-infrared tomographic imaging system. ConclusionsThese studies indicate that cathepsin B, and potentially other proteases, may serve as a biomarker for vulnerable plaques when probed with beacons. The tomographic in vivo imaging method as well as catheter-based optical sensing methods could be readily adapted to screening and potentially to the molecular profiling of a number of proteases in vulnerable plaque in vivo.
Revised on March 26, 2002
Accepted on March 27, 2002
In Vivo Imaging of Proteolytic Activity in
Atherosclerosis
Jiqiu Chen MD,
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |